Voyager Therapeutics Prepares for IPO

Health and Healthcare

Published: October 12, 2015 11:10 am

Voyager Therapeutics has filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). No terms were given in the filing but the offering is valued up to $88.25 million. The company intends to list on the Nasdaq Global Market under the symbol VYGR.

The underwriters for the offering are Cowen, Piper Jaffray, Nomura and Wedbush Pacgrow.

This is a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The company focuses on CNS diseases where it believes that an adeno-associated virus (AAV) gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact.

The company has created a product engine that enables it to engineer, optimize, manufacture and deliver its AAV-based gene therapies that have the potential to provide durable efficacy following a single administration directly to the CNS. The product engine has rapidly generated programs for five CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis, or a form of the disease caused by a single gene mutation; Friedreich’s ataxia; Huntington’s disease; and spinal muscular atrophy. Voyager’s most advanced clinical candidate, VY-AADC01, is being evaluated for the treatment of advanced Parkinson’s disease in an open-label, Phase 1b clinical trial with the goal of generating human proof-of-concept data in the second half of 2016. The founders and members of the management team have extensive experience in drug discovery and development and have pioneered significant advances within the fields of AAV gene therapy and neuroscience.

Voyager intends to use the net proceeds from this offering to fund the costs of future clinical development and to fund the costs of additional preclinical development, manufacturing and clinical development, including Phase 1 and later-stage clinical trials. The remainder of the proceeds will be used to fund working capital and other general corporate purposes.

ALSO READ: 8 Fresh Analyst Stock Picks With 50% to 100% Upside

Is Your Money Earning the Best Possible Rate? ^(Sponsor)

Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.

However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.

There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!